Coherus BioSciences Funding & Investors
Redwood City, CA
Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.
coherus.comTotal Amount Raised: $770,700,672
Coherus BioSciences Funding Rounds
Post Ipo Debt
$100,000,000
Post Ipo Debt Investors
Pharmakon AdvisorsPost Ipo Debt
$400,000,000
Post Ipo Debt Investors
Armentum PartnersPost Ipo Equity
$50,000,000
Post Ipo Equity Investors
Shanghai Junshi Biosciences CoPost Ipo Debt
$75,000,000
Post Ipo Debt Investors
HealthCare Royalty PartnersSeries C
$54,700,000
Series C Investors
KKRVenrockRa Capital ManagementRock Springs CapitalLilly VenturesSofinnovaVivo CapitalViva Capital AdvisorsF-Prime CapitalHelix VenturesKMG Capital PartnersEight Roads VenturesIPO
Unknown
Debt Financing
$28,000,700
Debt Financing Investors
Helix VenturesSeries B
$61,500,000
Series B Investors
Daiichi SankyoCook PharmicaMedpaceLilly VenturesHelix VenturesSeries A
$1,500,000
Series A Investors
Helix VenturesMedpace